Skip to main content

Advertisement

SpringerLink
Log in

CANCER IMMUNOTHERAPY

Adding to the checkpoint blockade armamentarium

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Antitumor immunity can be enhanced by blocking NKG2A, an inhibitory receptor expressed on natural killer and T cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Inhibition of NKG2A enhances cancer-immune interactions.

References

  1. van Montfoort, N. et al. Cell 175, 1744–1755 e1715 (2018).

    Article  Google Scholar 

  2. André, P. et al. Cell 175, 1731–1743 e1713 (2018).

    Article  Google Scholar 

  3. Bastidas-Legarda, L.Y. & Khakoo, S.I. Immunology http://doi.org/10.1111/imm.13039 (2018).

  4. Gooden, M. et al. Proc. Natl Acad. Sci. USA 108, 10656–10661 (2011).

    Article  CAS  Google Scholar 

  5. Bossard, C. et al. Int. J. Cancer 131, 855–863 (2012).

    Article  CAS  Google Scholar 

  6. Kim, N. & Kim, H. S. Front. Immunol. 9, 2041 (2018).

    Article  Google Scholar 

  7. Vermorken, J. B. et al. J. Clin. Oncol. 25, 2171–2177 (2007).

    Article  CAS  Google Scholar 

  8. Kreiter, S. et al. Nature 520, 692–696 (2015).

    Article  CAS  Google Scholar 

  9. Gubin, M. M. et al. Nature 515, 577–581 (2014).

    Article  CAS  Google Scholar 

  10. Massarelli, E. et al. JAMA Oncol. 5, 67–73 (2019).

    Article  Google Scholar 

  11. Gunturi, A., Berg, R. E., Crossley, E., Murray, S. & Forman, J. Eur. J. Immunol. 35, 766–775 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Matthew D. Hellmann

  2. Weill Cornell Medical College, New York, NY, USA

    Matthew D. Hellmann

  3. Merck, Rahway, NJ, USA

    Alexandra Snyder

Authors
  1. Matthew D. Hellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Snyder.

Ethics declarations

Competing interests

A.S. is an employee of and owns stock in Merck. M.D.H. receives research funding from Bristol-Myers Squibb; is a paid consultant to Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Janssen, Nektar, Syndax, Mirati, and Shattuck Labs; receives travel support and honoraria from AztraZeneca and BMS; and has filed a patent related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hellmann, M.D., Snyder, A. Adding to the checkpoint blockade armamentarium. Nat Med 25, 203–205 (2019). https://doi.org/10.1038/s41591-019-0350-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-019-0350-5

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation